CHRIS RALLIS - 11 Apr 2025 Form 4 Insider Report for FENNEC PHARMACEUTICALS INC. (FENC)

Role
Director
Signature
/s/ Chris Rallis
Issuer symbol
FENC
Transactions as of
11 Apr 2025
Transactions value $
-$6,975
Form type
4
Filing time
11 Apr 2025, 16:31:00 UTC
Previous filing
14 Feb 2025
Next filing
04 Jun 2025

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction FENC Common Shares Options Exercise $4,997 +2,173 +4.1% $2.30 55,193 11 Apr 2025 Direct F1
transaction FENC Common Shares Sale -$6,974 -1,409 -2.55% $4.95 53,784 11 Apr 2025 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction FENC Common Shares Options Exercise -$4,997 -2,173 -1.19% $2.30 180,533 11 Apr 2025 Options 2,173 $2.30 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 . Shares acquired through the exercise of an option pursuant to a 10b5-1 plan adopted on August 17, 2023.
F2 Shares sold to satisfy tax obligation on option exercise.
F3 Represents options exercised pursuant to a 10b5-1 plan adopted on August 17, 2023.